Quest Laborato.
: QUESTLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Quest Laborato.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Quest Laboratories Ltd is a pharmaceutical manufacturer specialising in a diverse range of therapeutic segments, including antibiotics, antimalarials, and diabetes treatments. The company produces ethical, generic, and over-the-counter drugs across various dosage forms such as tablets, liquids, and ointments.
Business Model
The company generates revenue through institutional supplies, domestic ethical product sales, PCD distribution, and contract manufacturing services. It leverages a portfolio of over 800 licensed formulations to serve both domestic and international markets.
- Licensed Formulations:800+
- Active Products:272+
Growth Outlook
Growth is supported by a strong focus on export markets and institutional supply contracts. The company maintains a significant order book, particularly within the Myanmar market, to drive near-term revenue.
- Myanmar Order Book:25cr.+
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality control and manufacturing standards that may impact operational continuity if not met.
- Geopolitical Risk. Reliance on specific international markets like Myanmar exposes the company to potential economic and political instability in those regions.
- Pricing Pressure. Intense competition in the generic and OTC drug segments may lead to margin compression and pricing volatility.
Start your research today
Unlock AI insights, financials, peers and live data on Quest Laborato. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Quest Laborato.QUESTLAB | ₹144 Cr | — | — | — | 16.0% | — | — | -10.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Quest Laborato.
: QUESTLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Quest Laborato.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Quest Laboratories Ltd is a pharmaceutical manufacturer specialising in a diverse range of therapeutic segments, including antibiotics, antimalarials, and diabetes treatments. The company produces ethical, generic, and over-the-counter drugs across various dosage forms such as tablets, liquids, and ointments.
Business Model
The company generates revenue through institutional supplies, domestic ethical product sales, PCD distribution, and contract manufacturing services. It leverages a portfolio of over 800 licensed formulations to serve both domestic and international markets.
- Licensed Formulations:800+
- Active Products:272+
Growth Outlook
Growth is supported by a strong focus on export markets and institutional supply contracts. The company maintains a significant order book, particularly within the Myanmar market, to drive near-term revenue.
- Myanmar Order Book:25cr.+
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality control and manufacturing standards that may impact operational continuity if not met.
- Geopolitical Risk. Reliance on specific international markets like Myanmar exposes the company to potential economic and political instability in those regions.
- Pricing Pressure. Intense competition in the generic and OTC drug segments may lead to margin compression and pricing volatility.
Start your research today
Unlock AI insights, financials, peers and live data on Quest Laborato. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026